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The goal of the present study was to develop a nanoemulsion (NE) system for efficient and 
prolonged delivery of Fingolimod Hydrochloride (FTY720; FT), to the posterior segment of 
the eye through the topical route. FT is a sphingosine-1-phosphate receptor agonist, an 
immunosuppressive agent. FT loaded NE (FT-NE) formulations were prepared with the 
homogenization method, using Soybean oil as lipid, Tween® 80 and Poloxamer 188 as 
surfactants. FT-NE were optimized based on particle size, zeta potential (ZP), Polydispersity 
Index (PDI) and assay. optimized FT-NE formulation were further evaluated for in vitro release 
and transcorneal in comparison with FT solution (FT-S) formulation, sterilization and stability 
studies. Optimized FT-NE formulation had a drug load of 0.3% w/v, showed a particle size, 
PDI, ZP and assay of 174.6±1.5 nm, 0.22 ± 0.01, 32.8 ± 1.9 mV and 97.5 ± 2.5%, respectively. 
The filtration studies indicated negligible process loss (< 1%) when filtered through PES 
0.22µm filters. FT-NE formulation was stable for 45 days and 90 days at room temperature 
and refrigerator conditions, respectively. In vitro release studies showed 50.1 ± 6.3% and 79.2 
± 2.6% drug release from FT-NE and FT-S over 24 h, indicating sustained release. 
Transcorneal permeation studies showed 2-fold and 5-fold increase between FT-S (0.15%) and 
FT-NE-S3 and FT-S (0.3%) and FT-NE-S2 formulations, respectively. The results from this 
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Anatomy of Eye 
Eye is the sight of organ. It is a very complex organ with multiple layers and a unique 
anatomy and physiology. The eye can be divided into two segments. The anterior segment 
consisting of cornea, conjuctiva, aqueous humor (AH), iris, ciliary body and lens, and the 
posterior segment which is made up of sclera, choroid, retinal pigment epithelium, neural 
retina, optic nerve and vitreous humor (VH). Various disease threatening the two segments of 
eye are glaucoma, allergic conjunctivitis, anterior uveitis and cataract for the anterior 
chamber while age-related macular degeneration (AMD) and diabetic retinopathy for the 
posterior segment of the eye. Due to ease of administration and patient compliance, almost 
90% of the ocular market consists of a topical eye drop as the preferred route and dosage 
form of treatment.1 Nonetheless, the ocular bioavailability is very low with the conventional 
topical eyedrop formulation.1 There are numerous anatomical and physiological reasons for 
the low ocular bioavailability of the topical ocular eyedrops. Few of the reasons which pose a 
challenge and impede deeper ocular drug permeation are tear turnover, nasolachrymal 
drainage, reflex blinking, and ocular static and dynamic barriers.1To overcome the ocular 






drug delivery systems have been developed such as emulsion, ointments, suspensions, 
aqueous gels, nanomicelles, nanoparticles, microneedles and in situ thermosensitive gels for 
the earlier mention ocular disease.  
Ocular Drug Delivery Approaches: 
There are various routes of drug administration to the ocular tissue. There are several possible 
routes for drug delivery into the ocular tissues. The selection of the administration route 
depends primarily on the target tissue. Traditionally, topical ocular and subconjunctival 
administrations are used for anterior targets and periocular, intravitreal, or systemic 
administration for posterior targets. 
Intavitreal administration 
To overcome the inefficiency and low bioavailability of topical delivery to the back of the eye 
and side effects of the parenteral delivery of the ocular drugs, the intravitreal administration of 
ocular drugs is employed. Primary advantages of this type of delivery system is that it directly 
delivers drug to the VH and retina, sustains drug levels, evades blood retinal barrier3.  
Topical conventional formulations 
Eye drops 
The formulations of eye drops possess a variety of factors that turn them into a widely 
prescribed form. They are safe, take immediate action after applied, have high patient-
compliance, are suitable for the product, and, above all, are non-invasive. Among the 
techniques used to get closer to an optimal bioavailability, excipients with diversified functions 
as cyclodextrins or enhancers of viscosity could be found. The relatively lipophilic membrane 
of the corneal tissue has low affinity for the hydrophilic cyclodextrin molecules and therefore 
they remain in the exterior aqueous membrane being cleared by the lacrimal fluid. As so, 




such as bioavailability of the encapsulated drugs, increased time of residence in the precorneal 
tissues, and higher solubility values2. 
Emulsions 
The formulations with an emulsion nature are keen to increase the bioavailability of the 
encapsulated drugs as well as the solubility. The principal formulative mechanism to yield this 
design is based on two types of emulsions—oil-in-water (O/W) and water-in-oil (W/O). To be 
applied in the delivery of drugs to ocular tissues the favorite type is the O/W rather than W/O, 
mainly due to the favorable characteristics as diminished irritation induced in the target tissues 
as well as improved tolerance of the eye to O/W emulsions2. 
Ointments 
Also included in the category of topical formulations ointments are used too as carrier systems 
for drug delivery. The usual melting points of these systems are near to the ocular temperature 
of 34 oC due to their constitution base on a combination of solid and semisolid hydrocarbon 
molecules.2 
Suspensions 
These pharmaceutical forms are chemically defined as being dispersions of drugs, using for 
such purpose a hydrophilic solvent possessing an agent of dispersion or a suspension obtaining 
a final solution with a saturated character. Furthermore, this type of formulation will be suitable 
once it does not require an invasive application method. The particles which constitute the 
suspension are taken by the precorneal tissue, enhancing the contact time of the drug with the 
tissues, and also increasing the period during which the drug is therapeutically active2.  
Advantages3:- 










a) Higher tear dilution 
b) Cornea acts as barrier 
c) Efflux pumps 
Novel topical delivery systems 
Nano-Enhanced Contact Lens 
Contact lenses cover the cornea using their curved shape and thin surface. Once applied they 
adhere to the wet surface in the exterior of the eye mainly due to surface tension phenomena. 
A vast range of drugs have been formulated to be delivered through the ocular route such as 
antihistamines, antimicrobials, and β-blockers. The existence of the contact lens allows the 
drug molecules to stay for longer periods in contact with the ocular tissue with increased flux 
crossing the cornea and less of the drug lost to the lacrimal duct. he common method to load 
the contact lens with a drug supply is to immerse them in a solution of a given drug. In 
performed studies the immersed contact lens demonstrated a better profile of release of drug 
in comparison to usual eye drops systems2. 
In situ gelling nanosystems 
The designation used refers to the solution with a polymeric nature that may experience a 
transition of phases between solution and gel forming then a gel presenting viscoelastic features 
as a result of a stimuli from the surroundings. The process of gelation is also prompted by other 
modifications such as pH variations, temperature, presence or absence of ions, and incidence 
by ultraviolet (UV) radiation. To develop and apply a system such as this in the ocular structure 





These systems are composed by vesicles of lipid nature arranged on a single or multiple 
phospholipid bilayer design with a hydrophilic core. Liposomal systems are classified based 
on their size and on their bilayers of phospholipids. As so, they can be categorized as small 
unilamellar, with sizes between 10 nm and 100 nm, large unilamellar, with a range of sizes 
between 100 nm and300 nm, and multilamellar if they have more than one bilayer and, so, are 
bigger than 300 nm [134,135].Regarding the ocular application route, liposomes are here 
described as suitable systems to deliver drug content because of their high efficiency to 
encapsulate both hydrophilic and lipophilic drugs, high biocompatibility, and a structure 
similar to the natural cell membrane. Liposome formulations were accurate enough to 
efficiently delivery their contents in the anterior and posterior portions of the eye, according to 
numerous scientific studies2. Major advantage of liposomal formulation is increase in the 
transcorneal permeation of the formulation3.  
Nanomicelles 
Nanomicelles possess exterior hydrophilic polar heads and an interior hydrophobic fatty 
acylchain which makes them capable of delivering poorly water-soluble drugs and of 
protecting molecules such as proteins or peptides. Such structures are amphiphilic and can 
possess in their nature an intrinsic capacity to be polymers or surfactants. The main advantages 
of such type of formulation are related with the ability to be easily prepared, the final small 
size they yield, and the tremendous capacity to encapsulate high quantities of drugs. As a direct 
consequence, the formulations carrying such morphology allow increased bioavailability of the 
drugs to be administered with further acquired improved clinical results2. 
Nanoparticles 
The nanoparticulate systems are chemically characterized as colloidal transporters ranging 
from10 nm to 1000 nm. In order to be applied in the ophthalmic tissues these arrangements 




as well as polymers from synthetic or natural sources, amongst them chitosan, albumin, sodium 
alginate, polylactic acid (PLA), poly(lactide-co-glycolide) (PLGA) or polycaprolactone. Also, 
the nanoparticle-encapsulating drugs may be divided in two principal devices: Nanocapsules 
and nanospheres. The first have the drug encapsulated in the interior of the polymeric lattice 
formed. The second have the drug homogeneously dispersed along the polymeric lattice2. As 
an alternative to the process of delivering of drugs to the posterior section of the eye, the 
nanoparticulate system aims to sustain the delivery for long periods. The main features which 
influence the penetration of nanoparticles into this portion are the size and the properties of the 
surface2. Advantages of nanoparticles includes enhanced corneal permeation and sustained 
release of drug from the formulation3. 
Nanosuspensions 
These formulations are obtained using surfactants or polymers to stabilize the particles 
constituted by drugs, but on a submicron range which, by turn, form colloidal dispersions. This 
system is quite appropriate to encapsulate hydrophobic drugs. Applying such formulation to 
the ocular route of delivery yields optimal outcomes when compared to other usual ophthalmic 
products—diminished irritation, better profile as eye drops, augmented half-life time in the 
precorneal tissue, sterilization of the product, and improved capacity to solubilize hydrophobic 
drugs in the lacrimal fluid2. 
Microneedles 
The technology based on the development and production of microneedles is based on a 
preference for minimal invasiveness. These microneedles possess the capacity to deliver a vast 
array of drugs to ocular tissues located in the posterior portion of the eye. Along with this, 
some aspects of the therapeutics may be overcome as the case of the intravitreal injections 
which possess many frightful consequences such as cataracts, endophthalmitis, hemorrhage, 





These materials are pharmaceutically engineered to deliver the drug cocktail content in a 
determined location during a specified time range preventing the prior requirement of several 
injections in the ocular tissues with further developing inflammatory processes and infections. 
If aimed to deliver the drug into the posterior portions of the ocular globe these implants are 
physically settled in the proper place through a surgical procedure that requires a small incision 
in the region of the pars plana, being anteriorly located to the retina but posteriorly to the lens.2 
Nanoemulsions (NE) 
NE formulations are a colloidal particulate system in the submicron size range acting as carriers 
of drug molecules. Their size varies from 10 to 1,000 nm4. These carriers are solid spheres and 
their surface is amorphous and lipophilic with a negative charge. Major application includes 
treatment of infection of the reticuloendothelial system (RES), enzyme replacement therapy in 
the liver, treatment of cancer, and vaccination. It is a thermodynamically unstable system, 
which can be stabilized by the presence of an emulsifying agent (emulgent or emulsifier)2. The 
dispersed phase is also known as internal phase or the discontinuous phase while the outer 
phase is called dispersion medium, external phase or continuous phase. The emulsifying agent 
is also known as intermediate or interphase. Because of small size, nanoemulsions are 
transparent. There are three types of nanoemulsion which can be formed: (a) oil in water 
nanoemulsion in which oil is dispersed in the continuous aqueous phase, (b) water in oil 
nanoemulsion in which water droplets are dispersed in continuous oil phase, and (c) 
bicontinuous nanoemulsions.  
Advantages of nanoemulsion  






 It improves the bioavailability of drug. It is non-toxic and non-irritant in nature.  
 It has improved physical stability.  
 Nanoemulsions have small-sized droplets having  greater surface area providing greater 
absorption.  
 It can be formulated in variety of formulations such as foams, creams, liquids, and 
sprays.  
 It provides better uptake of oil-soluble supplements in cell culture technology.  
 It helps to solubilize lipophilic drug.  
 Helpful in taste masking.  
 Less amount of energy is required.  
Disadvantages of Nanoemulsions5:- 
 Use of a large concentration of surfactant and cosurfactants necessary for stabilizing 
the nanodroplets. 
 Limited solubilizing capacity for high melting substances. 
 The surfactant must be nontoxic for pharmaceutical applications.  
 NE stability is influenced by environmental parameters such as temperature and pH. 
These parameters change upon NE delivery to patients. 
Fingolimod Hydrochloride (Figure 2) (FTY720; FT) acts as a modulator for four of five known 
sphingosine 1-phosphate (S1P) receptor subtypes (S1P1, S1P3, S1P4, and S1P5)6. Reported 









FT is an immunomodulating drug and S1P receptor modulator. Phosphorylation of FT by 
sphingosine kinase causes S1P1R internalization, which sequesters lymphocytes in lymph 
nodes, preventing them from taking part in an autoimmune response. Clinically, it has been 
approved for the treatment of multiple sclerosis (MS). 
The goal of the present study was to develop a NE system for efficient and prolonged delivery 
of FT, used as a model drug, to the posterior segment of the eye through the topical route. NE 
as a drug delivery system were utilized in our study for formulating FT as ocular eye drops in 
virtue of their distinct advantages. These include sustained release of the drug applied to the 
cornea, high penetration in the deeper layers of the ocular structure, and AH as well as ease of 
sterilization. Thus, these systems can achieve therapeutic action with a smaller dose and a fewer 











Tween® 80 NF, Poloxamer 188 NF, Glycerin USP and Soybean oil USP were purchased from 
Spectrum Chemicals (Gardena, CA, USA). d-α-tocopheryl polyethylene glycol 1000 succinate 
(TPGS) was obtains from Antares Healthcare Products, Inc. (St. Charles, IL, USA). FT was 
purchased from Sigma Aldrich (USA). Other chemicals and materials required for the project 
like HPLC grade solvents, centrifuge tubes, HPLC vials, scintillation vials were obtained from 
Fischer Scientific (Hampton, NH, USA). 
 
METHODS 
Preparation of FT-NE: 
FT loaded nanoemulsion (FT-NE) was prepared using homogenization and probe sonication 
method as per the composition in Table 1. The emulsion consisted of two phase: the lipid phase 
and aqueous phase. Lipid phase consists of soybean oil and drug and the aqueous phase consists 
of Tween® 80, Poloxamer 188, TPGS, glycerin and double distilled water (milli-Q-water).  
The lipid phase was heated at 80°C in a glass scintillation vial with continuous stirring at 2000 
rpm. Simultaneously, in a separate vial aqueous phase was heated to the same temperature as 
the lipid phase. On attaining the temperature, the aqueous phase was added to the lipid phase 
drop by drop with constant stirring to get a premix. This premix was homogenized at high 




emulsion. The pre-emulsion was placed in a beaker of ice (to reduce charring caused by excess 
heat) and then probe sonication for 10 minutes at 40% amplitude with pulse of 10 sec ON and 
15 sec OFF. The emulsion thus obtained was allowed to cool to room temperature to get the  
final formulation.  
 
Production parameters such as different rpm for ultra-Turrax®, probe sonication, different lipid 
concentartions and different ratios of lipid and surfactants in the formution were also tested.  
Preparation of FT solution (FT-S): 
Since no marketed preparation of FT exists, the FT solution is used as a control. FT-S of similar 
strength (0.15% w/v and 0.3% w/v) was made by adding the drug in Double Distilled  water 
and vortexing until the drug was seen to have completely dissolved.  















Soybean oil - - 5 5 5 5 
Castor oil 5 5 - - - - 
Fingolimod HCl 0.3 0.6 0.3 0.3 0.15 - 
d-α-tocopheryl 
succinate 
0.002 0.020 0.002 0.002 0.002 0.002 
Tween 80 0.75 0.75 0.75 2 2 2 
Poloxamer 188 0.2 0.2 0.2 0.2 0.2 0.2 
Glycerin 2.25 2.25 2.25 2.25 2.25 2.25 
Water (mL) QS 10ml QS 10ml QS 10ml QS 10ml QS 10ml QS 10ml 





A previously reported HPLC method was used for analysis of FT-NE’s.8 HPLC system 
comprised of Waters® 600 Controller equipped with in-line degasser, 717plus Autosampler 
and 2487 Dual λ absorbance detector. The column used was C8 Luna® 5µ (250 mm x 4.6 mm) 
and was protected by guard column. The mobile phase comprised of acetonitrile (ACN): 50 
mM potassium dihydrogen phosphate buffer with pH maintained at 3.0 in ratio 55:45 v/v, 
respectively. The elution flow rate was 1 mL/min. The detection wavelength was set at 220 nm 
and auto sampler was maintained at 4°C. Injection volume for each sample was 20 µL. 
CHARACTERIZATION OF FT-NE: 
Measurement of Particle size, zeta potential (ZP) and polydispersity index (PDI): 
ZP is the overall charge of the nanoformulation and its magnitude (positive or negative) 
indicates the physical stability of the colloidal system as higher the magnitude, more the 
repulsion and less is the aggregation (Riddick 1968). The hydrodynamic radius, PDI and ZP of 
the FT-NE formulation was determined by photon correlation spectroscopy at 25°C with 173° 
backscatter detection using a Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc., MA, 
USA). Clear disposable folded capillary cells (for particle size and PDI measurement) and 
special Zeta cells (for ZP measurement) were used to place the sample in Zetasizer. Particle 
size analysis data was evaluated based on the volume distribution for which about 10 µL of the 
sample was diluted up to 1000 µL (100 times dilution) using filtered double distilled (milli-Q) 
filtered through 0.2µm syringe filter. 
Drug content of FT-NE 






using 990 µL of ACN (FT is soluble in ACN) and vortexed quickly for 1 minute. This was 
further diluted by aliquoting100 µL into 900 µL of ACN. The 1000-fold diluted sample was 
then analyzed for FT content using the HPLC method as mentioned above. 
Drug-excipient compatibility study - Fourier transform infrared spectrophotometry 
(FTIR) 
The FTIR of pure drug, soyabean oil, physical mixture of oil and drug, placebo formulation 
and drug loaded formulation was collected using a bench top Fourier FTIR spectrometer 
(Agilent Technologies, Cary 660; Agilent, Santa Clara CA, USA) fitted with a MIRacle ATR 
sampling accessory (Pike Technologies, Madison WI, USA). The bench top ATR was 
equipped with a single bounce diamond-coated ZnSe internal reflection element. The 
transformation spectrum thus obtained was overlayed and compared for results.9 
Measurement of pH: 
The pH of FT-NE formulations (1mL) was measured using pH meter (Mettler Toledo, 
USA) after the preparation. The pH meter was calibrated every time using standard pH 
buffers 4.01, 7.00 and 10.01. 
Stability studies:  
Stability of the FT-NE formulation was studied at 4°C, 25°C and 40°C temperature conditions. 
At predetermined time intervals, the formulations were evaluated for particle size, ZP, PDI and  
content according to the procedures mentioned earlier. 
Sterilization: 
It is necessary that all ophthalmic formulations be sterile, making it a challenge for 






tried were sterile filtration and autoclave sterilization. Autoclave was done using the 
Autoclave (3850EL Tuttnauer, Germany) at 121C for 15 minutes at 15 psi pressure. 
Filtration studies were undertaken on the FT-NE formulations to check for stability issues 
post-filtration and also % drug loss during filtration. About 5 mL of FT-NE formulation 
was taken in a glass syringe with a 13 mm stainless steel filtration set  and filtered through 
0.22 µm PES and 0.22 µm Durapore membrane. Post-filtration the formulations were 
checked for drug content and physical and chemical characteristics and compared to the 
pre-filtration values. 
In vitro drug release study 
In vitro drug release studies of the optimized FT-NE formulations (0.3 % w/v and 0.15 %w/v) 
were performed in triplicate using a multi-station magnetic stirrer at 34 ± 0.5℃ to simulate the 
ocular surface temperature. FT-S used as control formulation. The receiving media was 
composed of 20 mL phosphate buffer saline (PBS; 10X) pH 7.4 and it was constantly stirred 
at 900 rpm throughout the experiment. Drug release studied through a semipermeable 
membrane (Slide-A-Lyzer® MINI Dialysis Devices, 10K molecular weight cutoff). At definite 
time intervals, 1 mL of the sample was withdrawn and replaced by fresh buffer to maintain a 
constant volume from receiver compartment. Drug concentration was determined 
chromatographically at 220 nm. Percent drug release was plotted as a function of time. 
Transcorneal drug release study:  
Freshly excised whole eye globes of rabbits were purchased from Pel-Freez® Biologicals. The 
eyes were stored in Hank's Balanced Salt Solution (HBSS) on ice and shipped overnight. The 
corneas were separated, washed with Phosphate Buffered Saline (PBS, pH = 7.4), and mounted 




the curvature of the cornea) for trans corneal studies. The water jacket around the cells was 
used to maintain a constant temperature (34 ± 0.2 °C) using a water circulator. The receiver 
cell had an orifice diameter of 0.636 cm2. The receptor chamber contained 3.5 mL isotonic 
PBS (IPBS) with 2.5% RM-β-CD, and the donor chamber (1 mL volume) contained 200 µL 
of FT-NE formulations. The FT solution (FT-S) was prepared as a control. Since no marketed 
preparation exists, the FT solution is used as a control. Aliquots of 1 mL were withdrawn and 





RESULTS AND DISCUSSIONS 
 
Formulation development and optimization of FT-NEs: 
The various FT-NE composition was selected and were analyzed. From the results, it has 
been observed that Tween® 80 and Poloxamer 188 together, help in reduction of particle size 
of the oil globules. Tween® 80 and Poloxamer 188 are non-ionic surfactants and are known 
to be less toxic surfactants as compared to cationic surfactants. Also, Tween® 80 is known to 
be well-tolerated emulsifier in the eye.10The FDA Inactive Ingredient Database (IIG) system 
limits were considered while using the concentration of  Tween® 80 of upto 4%w/v and 
Poloxamer of upto 0.2%.w/v. Lower particle size gives more surface area, better interaction 
with body fluids and helps in the transport of drug molecules to the anterior segment of eye 
by increasing the permeation across the ocular barriers. As a result, lower particle size and 
lower PDI are preferred. Thus, these parameters were considered of utmost importance while 
determining the processing parameters and other composition concentrations. Oil screening 
was performed before selecting the oil used in formulating the FT-NE’s. The oil screening 
data (Table 2) helped in determining the oil of interest in formulating the FT-NE’s. Castor oil 






and stable particle size and PDI (Table 3) and thus soyabean oil was selected as the oil of 
interest. Effect of Ultra-Turrax speed on coarse emulsion characteristics was studied at 
10,800 rpm, 11,000 rpm and 11,200 rpm for 5 minutes. From the results, coarse emulsion 
which were obtained at 11,000 rpm showed better size reduction as compared to 10,800 rpm 
and 11,200 rpm (Table 4). About 80% and 120% of the chosen speed was tested to determine 
if there was a significant difference between them. Since there was no significant difference 
11,000 rpm for 5 minutes was selected for preparation of the FT-NE. Two processing 
parameters, probe sonication time and mixing time were chosen using probe sonication and 
changing pulse for probe sonication, keeping the total probe sonication time of 10 min. 
The effect of lipid and surfactant concentrations on particle size and PDI was studied. Decrease 
in the Tween®80 concentration (Table 5). Increase in particle size and PDI were observed as 
the concentration of lipid was increased while keeping the surfactant concentration constant 
(Table 6). Nanoemulsions formulated with 5%w/v of soyabean oil, 2%w/v of Tween® 80, 
0.25% w/v of poloxamer 188 and 0.002%w/v of d-α-tocopheryl succinate showed less particle 
size and PDI. Hence, the above composition was selected for further evaluation. Table 1 shows 
the formulation composition for the FT-NE. Drug load of 0.3% was determined as the lower 
amount of drug load (0.15%w/v) did not show as great transcorneal permeability results as that 







Oil Solubility of FT (µg/mL) 
Castor Oil 3.9 ± 0.07 
Soybean Oil 13.8 ± 0.03 
Cottonseed Oil 0.3 ± 0.002 
Sesame Oil 0.3 ± 0.008 














Particle size (nm) PDI Particle size (nm) PDI 
10,800 179.9 ±1.4 0.20 ± 0.01 1019 ±100.6 0.97 ± 0.07 
11,000 173.5 ±1.8 0.24 ± 0.01 900 ±130.6 0.77 ± 0.02 





















0.37±0.008 0.27±0.01 0.27±0.02 







FT Particle size 
(nm) 
PDI 
5 0.25 0.75 0.3 202.3 ± 5 0.22 ± 0.02 
5 0.25 1 0.3 199.7 ±2.9 0.24 ± 0.03 
5 0.25 2 0.3 173.5 ±1.8 0.24 ± 0.01 
5 0.25 4 0.3 146.7 ± 3.4 0.21 ± 0.009 
Table 5: Effect of surfactant concentration on physical characteristics of FT-NE 
formulation (mean ± SD, n=3) 
Table 4: Effect of Ultra-Turrax® rpm and probe sonication on particle size and PDI 





Compatibility studies - FTIR 
FTIR studies were performed to determine the purity and interaction of the drug with physical 
mixture. The FTIR spectra was recorded for each of the following; FT, soybean oil, physical 
mixture of drug and oil, placebo FT-NE-P formulation and FT-NE formulations represented in 
Fig. 3. From the FTIR spectrum, it can be interpreted that the drug is pure since the 
characteristic wavelength numbers is similar to that present in the literature.11 Characteristic 
peaks, in the fingerprint region from 4000 cm-1 to 800 cm-1 were observed for both drug and 
oil. For the physical mixture, the spectra were identical to that of only oil indicating that the 
entire drug was completely solubilized in the oil. For the physical mixture, the ratio in which 
the oil and drug were used for analysis was similar to their ratio in the final formulation. The 
FTIR spectra for the FT-NE formulation and the FT-NE-P formulation was seen to be exactly 










Tween® 80 FTY720 Particle size (nm) PDI 
5 0.25 2 0.3 173.5 ± 1.8 0.24 ± 0.01 
15 0.25 2 0.3 401.8 ± 10.0 0.69 ± 0.03 
25 0.25 2 0.3 886.4 ± 20.4 0.47 ± 0.2 
Table 6: Effect of oil concentration on physical characteristics of FT-NE 






Figure 2: FTIR spectra of pure FT, soybean oil, physical mixture, placebo formulation 
and drug loaded formulation (down to up) 
 
Stability studies of optimized FT-NE: 
The chemical and physical stability of FT-NE-S2 was checked for 6 months at refrigerator 
(4oC), room (25oC) and accelerated (40oC) temperature conditions. The results are presented 
in Table 7. The physical appearance, physical and chemical parameters (pH, particle size, ZP, 
PDI and drug assay) were determined at specified time intervals. There was no physical 
separation or breaking observed, nor was there a difference in other recorded parameters up to 
6 months. In the case of formulations stored at 40oC, color difference was observed after 30 
days and for that of room temperature, the same was observed after 45 days. The difference in 
color change meant that the degradation product formed might be colored which was observed 
physically. The % assay also indicates the decrease in the percentage amount of drug over 30 
















1 170.3±1.7 0.26±0.02 50.3±0.8 110.64±1.4 
30 172±1.3 0.19±0.05 49.1±0.6 104.2±6.1 
60 178.5±1.1 0.24±0.01 43.1±2.4 102.4±3.4 
90 182.0±2.4 0.25±0.005 42.9±2.0 99.72±3.6 
180 190.7±1.2 0.25±0.01 40.5±1.5 93.1±1.8 
 
25 
1 195.3±3.6 0.24±0.002 53.8±1.4 104.5±2.8 
30 193.2±3.8 0.22±0.02 51.03±0.6 102.8±1.0 
60 172.5±0.5 0.25±0.03 49.4±0.5 97.0±5.0 
90 173.1±1.0 0.20±0.02 39.4±1.1 89.2±5.4 
180 Physically degraded 
40 
1 192.4±1.9 0.22±0.02 50.4±0.7 111.3±2.6 
30 185.1±1.8 0.26±0.03 49.1±0.6 90.26±3.5 
60 178.5±2.4 0.26±0.02 48.06±0.5 77.3±6.0 






1 182.8±0.6 0.24±0.02 40.6±0.9 113.9±2.9 
30 180.4±0.3 0.24±0.08 36.2±0.3 109.41±3.7 
60 179.5±3.4 0.23±0.02 35.2±0.8 
106.03±0.2
1 
90 177.5±0.8 0.23±0.01 31.5±0.3 101.8±3.4 
180 174.6±0.5 0.22±0.01 30.3±0.4 100.8±6.7 
 
25 
1 181.1±1.1 0.24±0.02 41.4±1.7 109.6±4.1 
30 179.5±3.4 0.24±0.01 40.6±0.9 108.6±3.4 
60 179.1±1.7 0.23±0.01 35.2±0.7 101.03±4.5 
90 177.7±4.5 0.25±0.007 11.5±0.3 80.4±2.4 
180 Physically degraded 
40 
1 179.5±3.4 0.25±0.007 42.8±1.3 102.6±0.8 
30 178.7±5.4 0.24±0.02 34.2±0.4 93.1±3.8 
60 176.1±2.8 0.24±0.01 14.7±0.8 77.3±6.0 




Table 7: Stability studies of optimized FT- NE at refrigerator (4°C), room (25°C) and 




pH of FT-NE 
The pH of the FT-NE formulations were checked at every stability study time point, to 
determine if there was any difference in pH. The pH of the FT-NE formulation was found to 
be in the range of 6-6.5, which is close to that of human tears (6.5-7.5). The pH of all batches 
was found to be within the above-mentioned range during the conduct of the stability study.  
Sterilization of FT-NE 
Stability of FT-NE formulation during sterilization was tested by subjecting the formulations 
to membrane filtration. Two different membranes (Durapore and PES) both having a pore size 
of 0.22 µm were used to evaluate the ease of filtration and the loss of drug caused by filtration 
of the FT-NE formulation. The formulations were found to be stable until 6 months (last point 
tested) indicating the potential for sterilization using membrane filtration method. The 
sterilized formulations were evaluated for parameters such as assay,  particle size, PDI, ZP and 
compared with the values before filtration (Table 8). The stability results of pre and post-
filtration of FT-NE using two different membranes is shown in Table 9. Filtration process 
decreased the particle size of the FT-NE and no significant difference was observed in PDI. 
After autoclaving the FT-NE, the formulations were found to be broken and complete phase 













Pre-filtration DP filtered PES filtered 











































































































































































































































































































Table 8: Effect of membrane filtration of FT-NE on physical characteristics 


















































































































































































































































































































































































































































































































In vitro drug release study: 
The in vitro drug release profiles of the  optimized FT-NE formulations are graphically 
illustrated in Figure 4. To facilitate comparison between release behaviors of different NE 
formulae, mean drug release (%; MDR) was calculated and the results are presented in Table 




10.  MDR is defined as Drug Release is the average percent drug release in each vial  in a 




















FT-S (0.15%) FT-NE-S3 FT-S (0.3%) FT-NE-S2
 Drug release (%) 
Time (h)  FT-S (0.15%) FT-NE-S3  FT-S (0.3%)  FT-NE-S2 
0.5 5.1±0.1 4.3±0.4 2.6±0.04 2.7±0.8 
1 6.9±0.03 5.4±0.2 3.5±0.2 2.9±0.4 
2 13.8±2.2 8.3±0.5 5.5±0.3 4.3±0.5 
3 13.7±0.1 10.9±0.9 7.2±0.4 5.7±0.9 
4 18.3±0.001 12.2±0.8 9.1±0.8 7.6±0.7 
6 29.7±1.2 17.9±1.6 8.9±0.9 13.9±0.9 
8 42.8±0.6 24.5±1.8 19.7±1.1 14.4±2.8 
12 65.9±0.9 38.1±2.9 34.8±2.8 23.7±4.4 
24 82.5±1.7 71.9±2.9 79.9±2.5 50.2±6.4 
Table 10: In vitro drug release profiles of FT-NE and FT-S formulation (mean± SD, 
n=3) 





From Figure 4, we can see that the FT-NE-S2 shows a very sustained release but the drug 
release overall is seen to be highly membrane dependant. The control solutions FT-S (0.15%) 
and FT-S (0.3%) show similar release while there is a difference of almost 20% in the release 
of FT-NE-S2 and FT-NE-S3 respectively. 
Transcorneal Permeation Study: 
The transcorneal drug permeation profiles of the optimized FT-NE formulations are 
graphically illustrated in Figure 5. To facilitate comparison between release behaviors of 
different NE formulae, MCDR (Mean Cummulative Drug Release) was calculated and the 
results are represented in Table 11. MCDR is the actual amount of drug released cumulatively 
is the amount in the PBS at any time plus the amounts you discarded from each sample. ( By 
removing a sample and replacing with fresh PBS, you are discarding the drug in each sample. 
The rate, flux and permeability are presented in Table 12. The transmembrane permeabilities 
of the FT-S (0.15%) (control) and FT-NE-S3 formulations were found to be 0.047±0.008 and 
0.076±0.018 cm/s, respectively (Figure 6) and transmembrane permeabilities of the FT-S 
(0.3%) (control) and  FT-NE-S2 formulations were found to be 0.057±0.032 and 0.275±0.019 
cm/s, respectively (Figure 6). The fluxes were found to be 0.028±0.006 and 0.046±0.026 
μg/min/cm2 for the FT-S (0.15%) and FT-NE-S3, respectively (Figure 7) and 0.034±0.023 and 
0.165±0.021 μg/min/cm2 for the FT-S (0.3% ) and FT-NE-S2, respectively (Figure 6).The 
transcorneal permeability and flux for FT-NE-S2 loaded NEs were significantly higher (∼5-
fold) in comparison to the FT-S (0.3%). The NEs enhance permeation by phagocytosis 
collision-mediated transfer of the drug from NEs to the cornea, thereby increasing the 






in comparison to the control, higher concentrations of FT would reach the retinal layer, thereby 
effectively preventing DR.  According to the obtained results, we see that there is a two fold 
increase in the transcorneal permeation of FT-S (0.15%) and FT-NE-S3. But there is almost a 
four- fold increase between the control solution FT-S (0.3%) and FT-NE-S2. Flux is the 









Cumulative amount permeated (mg) 
Time 
(min) 
 FT-S (0.15%) FT-NE-S3  FT-S (0.3%) FT-NE-S2 
15 0±0 0±0 2.0±0.2 3.6±0.8 
30 0.6±1.1 1.3±1.1 2.0±0.2 4.7±0.3 
45 0.03±0.04 1.4±1.2 2.2±0.1 5.4±0.1 
60 0.03±0.04 1.4±1.2 2.2±0.1 7.7±0.1 
90 2.0±0.1 1.5±1.3 2.3±0.1 11.2±0.6 
120 2.3±0.2 2.4±0.3 2.6±0.6 14.3±0.2 
150 2.6±0.4 2.8±0.9 3.4±1.7 16.2±0.8 
180 3.2±0.9 5.2±2.0 3.9±2.2 18.9±0.9 





FT-S (0.15%) 0.018±0.005 0.028±0.006 0.047±0.008 
FT-NE-S3 0.029±0.011 0.046±0.026 0.076±0.018 
FT-S (0.3%) 0.022±0.008 0.034±0.023 0.057±0.032 
FT-NE-S2 0.105±0.012 0.165±0.021 0.275±0.019 
Table 12: Flux and Permeability in Transcorneal permeation of FT-NE (mean±, n=3) 













































Figure 4: Transcorneal permeation vs time profiles of FT from FT-NE and FT-S 
formulations (mean±SD, n=3) 
Figure 5: Transcorneal permeability of FT from FT-NE and FT-S formulations 































































Figure 6: Transcorneal flux of FT from FT-NE and FT-S formulations 






























In this study, FTY720 (as model drug) loaded nanoemulsion formulation were successfully 
formulated and optimized, using soybean oil as the oil, Tween®80 and Poloxamer 188 as 
surfactants. Optimized formulation exhibited below 200 nm particle size with stable ZP. FTIR 
studies confirms the compatibility of the drug with excipients. The formulations were 
membrane filterable and were stable for three months at both refrigeration and room 
temperature. In vitro release studies revealed sustained release of FT from FT-NE formulation. 
About 5-fold increase in the FT permeation from optimized NE formulation, compared with 
FT solution as control formulation through isolated rabbit cornea was observed. Further studies 
evaluating the in-vivo activity of the formulations are needed. The formulated FT-NE shows a 
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